	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M IR	12M IR	12M IR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	274	393	509	546	597	721	848	982	1,074	1,212	1,347	1,685	2,009	2,894	3,129
Cost of Operating Revenue	54	78	105	115	125	133	165	197	235	290	331	483	586	1,070	1,075
Gross Profit	220	315	404	431	472	588	683	786	839	922	1,016	1,202	1,424	1,824	2,054
Gross Margin	80.5	80.1	79.4	79.0	79.1	81.6	80.5	80.0	78.1	76.1	75.4	71.3	70.9	63.0	65.6
Total Operating Expenses	219	311	415	440	443	474	552	673	752	824	923	1,263	1,515	2,191	2,289
Operating Profit	55	82	94	106	154	246	296	309	322	388	425	422	494	703	841
Operating Margin	20.2	21.0	18.5	19.4	25.8	34.2	34.9	31.4	30.0	32.0	31.5	25.0	24.6	24.3	26.9
Financing Income/(Expense) - Net	0	1	4	3	3	3	-5	-20	9	3	4	-17	-70	-223	-193
Profit before Taxes	55	83	98	109	121	270	312	317	331	394	442	405	431	489	639
Income Taxes	18	25	27	20	9	24	17	26	35	39	36	30	34	114	-9
Profit after Tax	37	58	71	89	111	247	294	291	296	355	406	382	392	352	620
PAT Margin	13.5	14.8	13.9	16.4	18.6	34.3	34.7	29.6	27.6	29.3	30.1	22.7	19.5	12.2	19.8
EPS - Basic - ex Extraordinary Items	2.69	4.23	5.15	6.49	8.09	17.95	21.39	21.15	21.61	26.16	29.89	28.10	28.82	25.85	45.33
EPS - Diluted - ex Extraordinary Items	2.69	4.23	5.15	6.49	8.09	17.95	21.39	21.13	21.59	26.14	29.88	28.07	28.79	25.82	45.26
EBIT	55	82	94	106	154	246	296	309	322	388	425	422	494	703	841
EBITDA	58	86	99	121	174	269	322	345	372	431	489	539	677	1,018	1,120
EBITDA Margin	21.3	21.9	19.4	22.3	29.2	37.4	38.0	35.2	34.6	35.5	36.3	32.0	33.7	35.2	35.8

Balance Sheet

Abridged

Understanding Balance Sheet

Eris Lifesciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	IR	IR	IR	IR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	69	126	155	163	159	216	299	582	480	467	627	765	2,302	1,223	1,540
Long-Term Investments	0	0	17	97	154	214	275	42	6	283	418	4	6	1	20
Property Plant & Equipment - Net	20	24	71	67	71	56	53	56	87	78	192	377	558	729	880
Total Non-Current Assets	33	45	115	194	259	511	1,161	972	1,073	1,368	1,645	2,903	4,738	5,810	5,826
Total Assets	102	172	271	357	419	727	1,460	1,554	1,552	1,835	2,272	3,667	7,040	7,033	7,366
Total Current Liabilities	35	44	71	65	69	76	225	306	165	167	200	443	2,532	1,381	2,077
Long Term Debt	3	1	-	1	-	0	274	0	6	4	80	683	692	1,782	996
Total Non-Current Liabilities	14	17	18	22	26	60	349	75	88	89	162	1,002	1,285	2,376	1,393
Total Liabilities	49	61	89	87	95	136	574	381	253	256	362	1,445	3,817	3,757	3,470
Total Shareholders' Equity	48	106	177	266	321	567	861	1,155	1,299	1,579	1,911	2,198	2,588	2,859	3,903
Minority Interest	5	5	4	4	3	24	25	18	-	0	0	25	636	417	-7
Total Equity	53	111	181	270	324	591	886	1,173	1,299	1,579	1,910	2,222	3,223	3,276	3,896
Total Liabilities & Equity	102	172	271	357	419	727	1,460	1,554	1,552	1,835	2,272	3,667	7,040	7,033	7,366

Cash Flow

Abridged

Understanding Cash Flow Statement

Eris Lifesciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M IR	12M IR	12M IR	12M IR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	41	55	69	98	140	217	248	256	323	370	409	448	514	798	805
Working Capital - Increase/(Decrease)	-11	-16	21	-8	-8	-16	-22	-54	-53	5	-30	-176	-99	126	-458
Net CF from Operating Activities	30	39	90	90	132	201	226	202	271	375	379	272	416	924	347
Capital Expenditures - Net	7	8	52	13	24	50	25	29	146	26	120	841	129	155	297
Net CF from Investing Activities	-21	-37	-83	-92	-44	-185	-591	-6	122	-325	-325	-986	-1,862	-84	-372
Dividends Paid - Cash - Total	6	-	-	-	83	17	-	-	47	75	82	100	-	100	-
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	1	-100	-	7	2	5	7	4
Debt - LT & ST - Issuance/(Retirement) - Total	-3	-2	-2	0	-1	-7	373	-200	-184	-6	34	809	1,463	-406	-125
Net Cash Flow from Financing Activities	-9	-2	-2	0	-84	-23	373	-199	-333	-81	-41	711	1,457	-736	-120
Free Cash Flow to Equity	21	28	36	78	108	145	574	-27	-59	343	293	240	1,749	364	-75
Free Operating CF net dividend	18	31	38	77	25	134	201	164	72	274	177	-669	287	669	50
Free Operating CF	24	31	38	77	108	151	201	164	119	349	258	-569	287	769	50

Business Segment Analysis

FY End:

Mar 25

Eris Lifesciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 155.00 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 2,893.64 Cr

Assets

Pharmaceuticals (100.0%)₹ 7,033.17 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 702.66 Cr

Regional Segment Analysis

FY End:

Mar 25

Eris Lifesciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (84.5%)₹ 2,637.50 CrOutside India (7.7%)₹ 241.76 CrOutside India (7.7%)₹ 241.76 Cr

Historical Segment Analysis

Track how Eris Lifesciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals	151	26	121	841	129	155

Frequently Asked Questions

What is the revenue of Eris Lifesciences Ltd.?

The latest trailing twelve month revenue of Eris Lifesciences Ltd. is ₹ 3,129.42 Cr, reflecting a 1-year growth of 8.15% and a 3-year CAGR of 22.92%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Eris Lifesciences Ltd.?

The latest trailing twelve month net profit (PAT) of Eris Lifesciences Ltd. is ₹ 619.52 Cr, with a 3-year earnings CAGR of 17.27%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Eris Lifesciences Ltd.?

The trailing twelve month EBITDA of Eris Lifesciences Ltd. is approximately ₹ 840.61 Cr (based on an operating margin of 26.86%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Eris Lifesciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Eris Lifesciences Ltd. is 45.26. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Eris Lifesciences Ltd.?

The debt-to-equity ratio of Eris Lifesciences Ltd. stands at 0.60. The interest coverage ratio is 4.36x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Eris Lifesciences Ltd.?

The estimated book value per share of Eris Lifesciences Ltd. is 281.62 (derived from a P/B ratio of 5.02 and market price of ₹ 1,413.90), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Eris Lifesciences Ltd.?

The trailing twelve month operating cash flow of Eris Lifesciences Ltd. is ₹ 346.93 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Eris Lifesciences Ltd. report consolidated or standalone financials?

Eris Lifesciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.